BOLD News and Press, Audentes Therapeutics Inc. From 11/05/18

SAN FRANCISCO , Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-F...

SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference c...

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Ensign Group, Inc. (NASDAQ:ENSG), Forterra, Inc. (NASDAQ:FRTA), ...

Audentes Therapeutics (NASDAQ: BOLD ) prices its public offering of 5.2M shares of common stock at a price of $29.00 per share, for expected gross proceeds of $150.8M. More news on: Audentes Therapeutics, Healthcare stocks news, Read more ...

SAN FRANCISCO , Oct. 10, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of...

SAN FRANCISCO , Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends...

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other im...

The following slide deck was published by Audentes Therapeutics in conjunction with this Read more ...

Audentes Therapeutics (NASDAQ: BOLD ) will present new positive interim data from ASPIRO, the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM) at the 23rd International Annual Congress of the World Muscle Society, on October 5. More news on...

SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (internationa...